Key result
Oral anti-coagulation alone showed no significant difference in major adverse cardiac events compared to combination therapy with a single anti-platelet agent.
Why the study?
Long term antithrombotic management in patients with stable CAD and AF remains unclear, with current guidelines based on weak recommendations and low quality evidence.
Does OAC alone compared to OAC plus single anti-platelet therapy improve outcomes in patients with stable coronary artery disease and atrial fibrillation?
Meta-Analysis (n=10,120)
Does OAC alone compared to OAC plus single anti-platelet therapy improve outcomes in patients with stable coronary artery disease and atrial fibrillation?
In patients with stable coronary artery disease and atrial fibrillation, OAC alone does not significantly differ from OAC plus single antiplatelet therapy in preventing major adverse cardiac events, but combination therapy is associated with a higher risk of major bleeding in RCT subgroups.
Answers are grounded in this paper and cite their sources.
OAC monotherapy suffices to prevent MACE in stable CAD with AF; confirms no added benefit from combination therapy while increasing bleeding risk.
INTRODUCTION: Long term management of patients with stable coronary artery disease of >1 year after myocardial infarction (MI) or percutaneous coronary intervention and atrial fibrillation is unclear. Current guidelines recommend using oral anti-coagulation (OAC) alone although the recommendation is weak and there is low quality evidence. Two new randomized control trials (RCTs) were published recently. We conducted an updated meta-analysis to evaluate the effect of these studies on patient outcomes. OBJECTIVE: To conduct a systematic review and meta-analysis of published RCTs and observational studies to compare OAC alone versus OAC plus single anti-platelet therapy. METHODS: Electronic searches were conducted using appropriate terms from 3 databases. Relevant studies included. Data extracted and analysis were performed using STATA. MEASUREMENTS: Summary statistics were pooled and measured for primary and secondary outcomes of both treatment arms. MAIN RESULTS: Eight studies involving 10,120 patients were included for the analysis. Five thousand two hundred thirty-seven patients were on combination therapy while 4883 were on OAC alone. There was no statistically significant difference in the primary outcome of major adverse cardiac events (hazard ratio [HR] 1.067; 95% confidence interval [CI] 0.912-1.249; P value .417). There was no statistically significant difference even in the measured secondary outcomes namely all cause mortality (HR 1.048; 95% CI 0.830-1.323; P value .695), cardiovascular mortality (HR 0.863; 95% CI 0.593-1.254; P value .439). However, we found statistically significant difference between the 2 groups in the incidence of MI with higher incidence in mono therapy group (HR 1.229; 95% CI 1.011-1.495; P value .039) and higher incidence of major bleeding in the combination therapy group in the subgroup analysis (HR 0.649; 95% CI 0.464-0.907; P value .011). CONCLUSION: We found no reduction of major adverse cardiac event between combination therapy and mono therapy. Although mono therapy showed increased risk of major bleeding overall, subgroup analysis of the RCTs showed increased risk of major bleeding in the combination therapy group. MI was higher in the mono therapy group compared to the combination therapy group, however this outcome was not reproducible in the subgroup analysis of the RCTs.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a meta-analysis in Stable coronary artery disease and atrial fibrillation (n=10,120). Oral anti-coagulation (OAC) alone vs. Oral anti-coagulation plus single anti-platelet therapy (OAC + SAPT) was evaluated on Major adverse cardiac events (MACE) (HR 1.067, 95% CI 0.912-1.249, p=.417). Oral anti-coagulation alone showed no significant difference in major adverse cardiac events compared to combination therapy with a single anti-platelet agent.
Synapse has enriched 10 related papers. Consider them for comparative context: